Regencell Bioscience Lim... (RGC)
Regencell Bioscience Statistics
Share Statistics
Regencell Bioscience has 13.01M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 13.01M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.24% |
| Shares Floating | 802.14K |
| Failed to Deliver (FTD) Shares | 48 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 10.86K, so 0.08% of the outstanding shares have been sold short.
| Short Interest | 10.86K |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.75% |
| Short Ratio (days to cover) | 1.37 |
Valuation Ratios
The PE ratio is -9.71 and the forward PE ratio is null. Regencell Bioscience's PEG ratio is 0.36.
| PE Ratio | -9.71 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 5.08 |
| P/FCF Ratio | -10.42 |
| PEG Ratio | 0.36 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Regencell Bioscience Limited.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 41.92, with a Debt / Equity ratio of 0.01.
| Current Ratio | 41.92 |
| Quick Ratio | 41.92 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.03 |
| Cash Flow / Debt | -46.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.52% and return on capital (ROIC) is -57.04%.
| Return on Equity (ROE) | -0.52% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -57.04% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-358,486.42 |
| Employee Count | 12 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 1558.57% in the last 52 weeks. The beta is -0.62, so Regencell Bioscience's price volatility has been lower than the market average.
| Beta | -0.62 |
| 52-Week Price Change | 1558.57% |
| 50-Day Moving Average | 7.91 |
| 200-Day Moving Average | 6.57 |
| Relative Strength Index (RSI) | 95.36 |
| Average Volume (20 Days) | 639.01K |
Income Statement
| Revenue | n/a |
| Gross Profit | -745.59K |
| Operating Income | -4.74M |
| Net Income | -4.3M |
| EBITDA | -3.62M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 2.96M in cash and 85.74K in debt, giving a net cash position of 2.88M.
| Cash & Cash Equivalents | 2.96M |
| Total Debt | 85.74K |
| Net Cash | 2.88M |
| Retained Earnings | -21.62M |
| Total Assets | 8.44M |
| Working Capital | 7.92M |
Cash Flow
In the last 12 months, operating cash flow was -4M and capital expenditures -5.38K, giving a free cash flow of -4.01M.
| Operating Cash Flow | -4M |
| Capital Expenditures | -5.38K |
| Free Cash Flow | -4.01M |
| FCF Per Share | -0.31 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RGC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.57% |
| FCF Yield | -0.53% |
Analyst Forecast
Currently there are no analyst rating for RGC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 1595.9 |
| Piotroski F-Score | 2 |